Takeda Reports FY2017 Full Year Results and Issues FY2018 Guidance

OSAKA, Japan–(BUSINESS WIRE)–May 14, 2018–Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +5.5% led by Takeda’s Growth Drivers Underlying Revenue grew +5.5%, with Takeda’s Growth Drivers (Gastroenterology, Oncology …
( read original story …)


Related Post

Japan deploys missile defence over North Korea thr...
views 260
The government hopes to complete deployment of the...
In testing missile, North Korea challenges South&#...
views 278
The launch, which Tokyo said could be of a new typ...
Starhill Global REIT Sells Nakameguro Place Proper...
views 105
Following my updates on Starhill Global REIT’s rec...
As Nikkei rally falters, how solid is its earnings...
views 161
Japan’s Nikkei 225 has ridden the same roller-coas...
5.9-Magnitude Earthquake Felt In Tokyo, No Tsunami...
views 79
A 5.9-magnitude earthquake hit Japan Saturday even...
Japan to stay vigilant on forex risks: chief cabin...
views 234
One crucial area in which I am charged to manage r...
Slow earthquakes could reveal how tsunamis start
views 261
The researchers found a series of slow slip events...
Japan bank CEO quits over claims of $2.2 billion i...
views 195
TOKYO: The head of a government-backed Japanese ba...
Japan’s rate decision lifts bonds, shares un...
views 56
LONDON (Reuters) - Reassurance by the Bank of Japa...
Japan stocks higher at close of trade; Nikkei 225 ...
views 166
Investing.com – Japan stocks were higher after the...